Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thoratec seeks EU nod for HeartMate II:

This article was originally published in Clinica

Executive Summary

Thoratec has filed an application in Europe to market its next generation heart assist device, HeartMate II, for long-term support. The application is based on data from the first 20 patients who were implanted with the device in the firm's phase I US trial and in a European study. These patients accounted for nearly 5,200 days of cumulative support and were each supported from 3-490 days. The Pleasanton, California firm said it hoped to CE-mark the device for sale this year. The HeartMate II is a left ventricular assist system for providing long-term cardiac support for patients who are in end-stage heart failure. It is currently being assessed in the US in a phase II trial, which is testing the product for both destination therapy and bridge-to-transplantation applications.

You may also be interested in...

COVID-19 Trial Changes Are “Propulsive Force” For Digital Adoption

Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.

Digital Doublespeak: The Language Barrier When Tech Companies Meet Regulators

A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”

ACC 2020: Medtronic’s Resolute Onyx DES Meets Goals In US/Japan Low-Risk Trial

The Onyx One Clear study, evaluating the Resolute Onyx drug-eluting stent in high bleeding risk patients, met its primary endpoint at the one-year follow up.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts